ERBB2 and breast carcinoma: In 2001, Peru et al. applied complementary DNA microarray technology to detect postoperative specimens, and divided breast cancer into different subtypes with different clinical prognosis, namely luminal A, luminal B, basal-like, HER2 overexpression, and normal-like type [19].